Tumor targeting effects of a novel modified paclitaxel-loaded discoidal mimic high density lipoproteins

References

• Alessandro C, Luisa C, Bernardetta M, et al. (2012). LCAT cholesterol esterification is associated with the increase of ApoE/ApoA-I ratio during atherosclerosis progression in rabbit. J Physiol Biochem 68:541–53
   PubMed Web of Science ®Google Scholar
• Cao WM, Murao K, Imachi H, et al. (2004). A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res 64:1515–21
   PubMed Web of Science ®Google Scholar
• Ding Y, Wang W, Feng MQ, et al. (2012). A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials 33:8893–905
   PubMed Web of Science ®Google Scholar
• Eirini MT, Maria SB, Elisavet HF, et al. (2010). HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis 208:3–9
   PubMed Web of Science ®Google Scholar
• Gessner A, Lieske A, Paulke B, Muller R. (2002). Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis. Eur J Pharm Biopharm 54:165–70
   PubMed Web of Science ®Google Scholar
• Jae YS, Yoosoo Y, Paul H, et al. (2012). pH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy. Int J Nanomedicine 7:2805–16
   PubMed Web of Science ®Google Scholar
• Jain SK, Chaurasiya A, Gupta Y, et al. (2008). Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targeting. J Microencapsul 25:289–97
   PubMed Web of Science ®Google Scholar
• Jia JT, Xiao Y, Liu JP, et al. (2012). Preparation, characterizations, and in vitro metabolic processes of paclitaxel-loaded discoidal recombinant high-density lipoproteins. J Pharm Sci 101:2900–8
   PubMed Web of Science ®Google Scholar
• Jie L, Li ZX, Jeffrey IZ, Fuyuhiko T. (2012). In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug delivery system: enhanced efficacy by folate modification. Nanomedicine: N.B.M 8:12–20
   PubMedGoogle Scholar
• Kim SI, Shin D, Lee H, et al. (2009). Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes. J Hepatol 50:479–88
   PubMed Web of Science ®Google Scholar
• Kistler P, Nitschmann H. (1962). Large scale production of human plasma fractions. Vox Sang 7:414–24
   PubMed Web of Science ®Google Scholar
• Lacko AG, Nair M, Paranjape S, et al. (2002). High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res 22:2045–9
   PubMed Web of Science ®Google Scholar
• Lee PY, Zhang RZ, Li V, et al. (2012). Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation. Int J Nanomedicine 7:731–7
   PubMed Web of Science ®Google Scholar
• Li C, Cui J, Wang C, et al. (2008). Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy. Eur J Pharm Biopharm 70:657–65
   PubMed Web of Science ®Google Scholar
• Liadaki KN, Liu T, Xu S, et al. (2000). Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I. J Biol Chem 275:21262–71
   PubMed Web of Science ®Google Scholar
• Maha S, Olga BG, Elizabeth B, et al. (2008). Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most efficient for tumor-specific treatment and imaging? J Control Release 130:107–14
   PubMed Web of Science ®Google Scholar
• Marina GD, Kannan M, Sushant T, et al. (2012). Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery. Adv Drug Deliv Rev 65:649--62
   Google Scholar
• McConathy WJ, Nair MP, Paranjape S, et al. (2008). Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs 19:183–8
   PubMed Web of Science ®Google Scholar
• Mineo C, Philip WS. (2012). Functions of scavenger receptor class B, type I in atherosclerosis. Curr Opin Lipidol 23:487–98
   PubMed Web of Science ®Google Scholar
• Mooberry LK, Nair M, Paranjape S, et al. (2010). Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J Drug Target 18:53–8
   PubMed Web of Science ®Google Scholar
• Murakami T. (2012). Phospholipid nanodisc engineering for drug delivery systems. Biotechnol J 7:762–7
   PubMed Web of Science ®Google Scholar
• Nobecourt E, Davies M, Brown B, et al. (2007). The impact of glycation on apolipoprotein AI structure and its ability to activate lecithin: cholesterol acyltransferase. Diabetologia 50:643–53
   PubMed Web of Science ®Google Scholar
• Rader DJ. (2006). Molecular regulation of HDL metabolism and function: Implications for novel therapies. J Clin Investig 116:3090–100
   PubMed Web of Science ®Google Scholar
• Rensen PCN, de Vrueh RLA, Kuiper J, et al. (2001). Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev 47:251–76
   PubMed Web of Science ®Google Scholar
• Roosbeek S, Vanloo B, Duverger N, et al. (2001). Three arginine residues in apolipoprotein AI are critical for activation of lecithin: cholesterol acyltransferase. J Lipid Res 42:31–40
   PubMed Web of Science ®Google Scholar
• Sabnis N, Lacko A. (2012). Drug delivery via lipoprotein-based carriers: answering the challenges in systemic therapeutics. Ther Deliv 3:599–608
   PubMedGoogle Scholar
• Tufteland M, Ren G, Ryan R. (2008). Nanodisks derived from amphotericin B lipid complex. J Pharm Sci 97:4425–32
   PubMed Web of Science ®Google Scholar
• Wang L, Chen WZ, Wu MP. (2010). Apolipoprotein A-I inhibits chemotaxis, adhesion, activation of THP-1 cells and improves the HDL inflammatory index. Cytokine 49:194–200
   PubMed Web of Science ®Google Scholar
• Wei Z, Yuan S, Yan Z, et al. (2011). The potential of Pluronic polymeric micelles encapsulated with paclitaxel for the treatment of melanoma using subcutaneous and pulmonary metastatic mice models. Biomaterials 32:5934–44
   PubMed Web of Science ®Google Scholar
• Xu Y, Jin XF, Ping QN, et al. (2010). A novel lipoprotein-mimic nanocarrier composed of the modified protein and lipid for tumor cell targeting delivery. J Control Release 146:299–308
   PubMed Web of Science ®Google Scholar
• Yan H, Yong H, Xiang F, et al. (2011). Anti-tumor activity of biodegradable polymer-paclitaxel conjugate micelles on lewis lung cancer mice models. J Biomater Sci Polymer Ed 22:1131--46
   Google Scholar
• Yuta Y, Yusuke K, Kenichi O, et al. (2011). PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. Int J Pharm 412:132–41
   PubMedGoogle Scholar
• Zhang MY, Jia JT, Liu JP, et al. (2012). A novel modified paclitaxel-loaded discoidal recombinant high-density lipoproteins: preparation, characterizations and in vivo evaluation. Asian J Pharm Sci 7:364–73
   Google Scholar
• Zhang WL, He HL, Liu JP, et al. (2013). Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins. Biomaterials 34:306–19
   PubMed Web of Science ®Google Scholar
• Zhang WL, Xiao Y, Liu JP, et al. (2011). Structure and remodeling behavior of drug-loaded high density lipoproteins and their atherosclerotic plaque targeting mechanismin foam cell model. Int J Pharm 419:314–21
   PubMed Web of Science ®Google Scholar